Shoreline Biosciences Wins a Comprehensive Summary Judgement Victory on All Claims Brought by Fate Therapeutics and Whitehead Institute on iPSC Generation and Use
Shoreline Biosciences to Participate at the 2023 Wedbush Pacgrow Healthcare Conference
California Life Sciences awarded Kite Pharma, a Gilead company, and Shoreline Biosciences the 2021 Strategic Partnership of the Year Award
https://shorelinebio.com//wp-content/uploads/2021/11/CA-Life-Sciences-Pantheon-Awards-2021.mov Shoreline Biosciences, Inc. is thrilled and honored to be recognized by the California Life Sciences (CLS) as the #Pantheon2021 award winner for the Strategic Partnership of the Year Award.
Developing Allogeneic Induced Pluripotent Stem Cell Based Therapies to Kill Cancer Cells with Kleanthis Xanthopoulos Shoreline Biosciences
Nov 4, 2021 Kleanthis Xanthopoulos is Co-Founder and CEO of Shoreline Biosciences. He talks about the Shoreline cell therapy platform that uses standardized manufacturing of allogeneic
Shoreline Biosciences – (iPSC)-Derived Allogeneic Natural Killer (NK) and Macrophage Products
Dr. Kleanthis Xanthopoulos, co-founder, Chairman and CEO of Shoreline Biosciences, discusses the development of genetically engineered induced pluripotent stem cell (iPSC)-derived allogeneic natural killer (NK) and
Fresh off Kite and BeiGene deals, Shoreline ups the ante with a hefty crossover
Editor: Max Gelman Though it may seem like Shoreline Biosciences is rapidly gaining momentum with a flurry of deals — and, now, a new funding round
[Video]Working with Natural Born Killers: Using Natural Killer Cells to Improve Cancer Immunotherapies
Putting ‘Super’ in Natural Killer Cells
Deleting an inhibitory gene in natural killer cells derived from induced pluripotent stem cells is found to boost their anti-tumor activity and persistence; researchers now
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
Shoreline to obtain an exclusive license to SLEEK knock-in technology for iPSC-derived NK cells, an exclusive license to SLEEK for iPSC-derived macrophages in oncology and
Shoreline Biosciences Announces Oral Presentation on Novel Manufacturing Method of Ink Cells at The 64th American Society of Hematology (ASH) 2022 Meeting
SAN DIEGO, Dec. 5, 2022 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its
Shoreline Biosciences Announces Appointment of Cell Therapy Manufacturing Veteran Charles Calderaro III as Chief Technical Officer
SAN DIEGO, Oct. 24, 2022 / — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing
Shoreline Biosciences to Present Two Posters on Ink Cell Platform At 19th Meeting of The Society for Natural Immunity (NK2022)
SAN DIEGO, May 10, 2022 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its
Shoreline Biosciences Presents Data at AACR 2022 Demonstrating its Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells
SAN DIEGO, April 12, 2022 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its
Shoreline Biosciences Announces Oral Presentation on iPSC-Derived NK Cell (iNK) Platform at Innate Killer Summit Meeting 2022
San Diego, Calif., March 28, 2022 – Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs)